Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib in HRD-positive metastatic castration-resistant prostate cancer
2018-002587-28Phase 2Terminated
- Sponsor
- BeiGene
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamiparib in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC), sponsored by BeiGene. Primary endpoint: Objective response rate. Started Apr 2019; status: terminated.
02
Drugs
pamiparib
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2018-002587-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002587-28.